Yong Wang1, Chun Li2, Qiyan Wang3, Tianjiao Shi4, Jing Wang5, Hui Chen6, Yan Wu7, Jing Han8, Shuzhen Guo9, Yuanyuan Wang10, Wei Wang11. 1. Beijing University of Chinese Medicine, Beijing, 100029, China. doctor_wangyong@163.com. 2. Modern Research Center for Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China. 34451574@qq.com. 3. Beijing University of Chinese Medicine, Beijing, 100029, China. wangqybucm@163.com. 4. Beijing University of Chinese Medicine, Beijing, 100029, China. tianjiaoshi1988@sina.cn. 5. Modern Research Center for Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China. wangjingbucm@163.com. 6. Beijing University of Chinese Medicine, Beijing, 100029, China. chbucm@163.com. 7. Beijing University of Chinese Medicine, Beijing, 100029, China. yanwubucm@163.com. 8. Beijing University of Chinese Medicine, Beijing, 100029, China. hanjingbucm@sina.com. 9. Beijing University of Chinese Medicine, Beijing, 100029, China. shuzhenguo@sina.cn. 10. Beijing University of Chinese Medicine, Beijing, 100029, China. yybucm@163.com. 11. Beijing University of Chinese Medicine, Beijing, 100029, China. wangwei26960@126.com.
Abstract
BACKGROUND: Danqi Pill (DQP), which contains Chinese herbs Salvia miltiorrhiza Bunge and Panax notoginseng, is widely used in the treatment of myocardial ischemia (MI) in China. Its regulatory effects on MI-associated lipid metabolism disorders haven't been comprehensively studied so far. We aimed to systematically investigate the regulatory mechanism of DQP on myocardial ischemia-induced lipid metabolism disorders. METHODS: Myocardial ischemia rat model was induced by left anterior descending coronary artery ligation. The rat models were divided into three groups: model group with administration of normal saline, study group with administration of DanQi aqueous solution (1.5 mg/kg) and positive-control group with administration of pravastatin aqueous solution (1.2 mg/kg). In addition, another sham-operated group was set as negative control. At 28 days after treatment, cardiac function and degree of lipid metabolism disorders in rats of different groups were measured. RESULTS: Plasma lipid disorders were induced by myocardial ischemia, with manifestation of up-regulation of triglyceride (TG), low density lipoprotein (LDL), Apolipoprotein B (Apo-B) and 3-hydroxy-3-methyl glutaryl coenzyme A reductase (HMGCR). DQP could down-regulate the levels of TG, LDL, Apo-B and HMGCR. The Lipid transport pathway, fatty acids transport protein (FATP) and Carnitine palmitoyltransferase I (CPTI) were down-regulated in model group. DQP could improve plasma lipid metabolism by up-regulating this lipid transport pathway. The transcription factors peroxisome proliferator-activated receptor α (PPARα) and retinoid X receptors (RXRs), which regulate lipid metabolism, were also up-regulated by DQP. Furthermore, DQP was able to improve heart function and up-regulate ejection fraction (EF) by increasing the cardiac diastolic volume. CONCLUSIONS: Our study reveals that DQP would be an ideal alternative drug for the treatment of dyslipidemia which is induced by myocardial ischemia.
BACKGROUND: Danqi Pill (DQP), which contains Chinese herbs Salvia miltiorrhiza Bunge and Panax notoginseng, is widely used in the treatment of myocardial ischemia (MI) in China. Its regulatory effects on MI-associated lipid metabolism disorders haven't been comprehensively studied so far. We aimed to systematically investigate the regulatory mechanism of DQP on myocardial ischemia-induced lipid metabolism disorders. METHODS:Myocardial ischemiarat model was induced by left anterior descending coronary artery ligation. The rat models were divided into three groups: model group with administration of normal saline, study group with administration of DanQi aqueous solution (1.5 mg/kg) and positive-control group with administration of pravastatin aqueous solution (1.2 mg/kg). In addition, another sham-operated group was set as negative control. At 28 days after treatment, cardiac function and degree of lipid metabolism disorders in rats of different groups were measured. RESULTS: Plasma lipid disorders were induced by myocardial ischemia, with manifestation of up-regulation of triglyceride (TG), low density lipoprotein (LDL), Apolipoprotein B (Apo-B) and 3-hydroxy-3-methyl glutaryl coenzyme A reductase (HMGCR). DQP could down-regulate the levels of TG, LDL, Apo-B and HMGCR. The Lipid transport pathway, fatty acids transport protein (FATP) and Carnitine palmitoyltransferase I (CPTI) were down-regulated in model group. DQP could improve plasma lipid metabolism by up-regulating this lipid transport pathway. The transcription factors peroxisome proliferator-activated receptor α (PPARα) and retinoid X receptors (RXRs), which regulate lipid metabolism, were also up-regulated by DQP. Furthermore, DQP was able to improve heart function and up-regulate ejection fraction (EF) by increasing the cardiac diastolic volume. CONCLUSIONS: Our study reveals that DQP would be an ideal alternative drug for the treatment of dyslipidemia which is induced by myocardial ischemia.
Authors: Stephen J Crozier; Douglas R Bolster; Ali K Reiter; Scot R Kimball; Leonard S Jefferson Journal: Am J Physiol Endocrinol Metab Date: 2002-08-20 Impact factor: 4.310
Authors: James P Hardwick; Douglas Osei-Hyiaman; Homer Wiland; Mohamed A Abdelmegeed; Byoung-Joon Song Journal: PPAR Res Date: 2010-03-16 Impact factor: 4.964